---
document_datetime: 2023-09-21 18:06:21
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/regranex-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: regranex-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.2139649
conversion_datetime: 2025-12-25 07:37:26.108922
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Regranex

Procedural steps taken and scientific information after the authorisation

<!-- image -->

| No        | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3 Summary longer   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|-------------------------------------------------|
| IB/0037/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the active substance- replacement or addition of a site where batch control/testing takes place, A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the | 11/10/2010 product                  | n/a no                                      | Annex II                                        |

7 Westferry Circus

●

Canary Wharf

●

London E14 4HB

●

United Kingdom

Telephone +44 (0)20 7418 8400 Facsimile +44 (0) 20 7523 7455

E-mail

info@ema.europa.eu Website www.ema.europa.eu

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| No       | Scope                                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                    |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|          | Change in the manufacturer of the active substance.                                                                                                              |                                     |                                             |                                  | authorised                                                                                                                                                                                                                                                                                                                                                                                 |
| A20/0033 | Article 20 Review                                                                                                                                                | 24/06/2010                          | 01/09/2010                                  |                                  |                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0036  | 12_Minor change of manufacturing process of the active substance Addition of an in-process control (IPC) applied during the manufacture of the active substance. | 24/06/2010                          | 30/06/2010                                  | longer                           |                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0034  | Update of Summary of Product Characteristics, Labelling and Package Leaflet                                                                                      | 22/10/2009                          | 20/11/2009 no                               | SPC, Labelling, PL               |                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0032  | Change(s) to the manufacturing process for the active substance Changes to the manufacturing process for the active substance.                                   | 19/03/2009 product                  | 24/03/2009                                  |                                  |                                                                                                                                                                                                                                                                                                                                                                                            |
| R/0031   | Renewal of the Marketing Authorisation Medicinal                                                                                                                 | 22/01/2009                          | 19/03/2009                                  | SPC, Annex II, Labelling, PL     | Based upon the data that have become available since the last renewal, the CHMP considers that the benefit-risk balance of Regranex remains positive, but considers that its safety profile is to be closely monitored for the following reasons: The efficacy of Regranex over the placebo is modest and there are concerns over the possible risk of cancer. More specifically, the CHMP |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No      | Scope                                                                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |                                                                                                                                                                                           |                                     | no                                          | longer                           | is concerned over the data collected from an extension to the cohort study, investigating the risk of neoplasms both local to the application site and distant. In the CHMP's view, it is unclear whether there is a possibility of an increased risk of cancer from using Regranex. This safety concern should be continuously monitored in the coming years. Further information is expected to be provided by the Marketing Authorisation Holder (MAH), to allow this issue to be evaluated in more depth. Therefore, based upon the safety profile of Regranex the CHMP concluded that the MAH should submit one additional renewal authorised |
| IB/0029 | 38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient, 31_b_Change to in-process tests/limits during manufacture - addition of new tests/limits | 24/07/2008 product                  | n/a                                         |                                  | application in 5 years time.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0030 | 04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                           | 15/07/2008                          | n/a                                         | Annex II                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0028 | 04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                           | 10/06/2008                          | n/a                                         | Annex II                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                |
|---------|-------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| N/0026  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)            | 04/12/2007                          | n/a                                         | PL                               | authorised                                                                                                                             |
| N/0025  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)            | 03/08/2007                          | n/a                                         | PL                               |                                                                                                                                        |
| N/0024  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)            | 14/08/2006                          | n/a                                         | PL                               |                                                                                                                                        |
| II/0020 | Change(s) to the manufacturing process for the active substance                                             | 28/06/2006                          | 03/07/2006                                  | longer                           |                                                                                                                                        |
| IA/0023 | 08_a_Change in BR/QC testing - repl./add. of batch control/testing site                                     | 22/06/2006                          | n/a no                                      |                                  |                                                                                                                                        |
| IA/0021 | 31_a_Change to in-process tests/limits during manufacture - tightening of in-process limits                 | 11/04/2006                          | n/a                                         |                                  |                                                                                                                                        |
| IA/0022 | 12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec. Medicinal | 11/04/2006 product                  | n/a                                         |                                  |                                                                                                                                        |
| N/0019  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)            | 29/03/2006                          | n/a                                         | PL                               |                                                                                                                                        |
| II/0018 | Update of Summary of Product Characteristics and Package Leaflet                                            | 17/11/2005                          | 23/12/2005                                  | SPC, PL                          | After the evaluation of the 8th Periodic Safety Update Report (PSUR), the CHMP recommended to the MAH that the advice regarding not to |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         | This variation relates to an update of the Summary of Product Characteristics (SPC) in order to move a warning regarding infected ulcers from section 4.4 of the SPC to 4.3 (as a contraindication) and to include \"osteomyelitis\" and \"cellulitis\" in section 4.8, as requested by the CHMP following the assessment of the 8th PSUR and a clinical study performed as a post- approval commitment. Relevant sections of the Package Leaflet (PL) were updated. | product                             | no                                          | longer                           | use Regranex in the presence of infection should be included in Section 4.3 of the SPC (as a contraindication) rather than as a special warning under Section 4.4. The MAH conducted an analysis of the ADR reports of infections and a characterisation of the frequency of these reactions. The conclusion was that the proper diagnosis and treatment of lower extremity infections was complicated and a delay in the treatment with antibiotics might result in serious complications. Additionally, as a result of the number of case reports on osteomyelitis and cellulitis received in the PSURs, the CHMP, after the evaluation of the 8th PSUR, requested that \"osteomyelitis\" and \"cellulitis\" should be added to Section 4.8 of the SPC in order to supplement and specify the term \"infections\". The Package Leaflet was also updated to reflect the above. authorised |
| N/0017  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                 | 13/09/2005                          | n/a                                         | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0015 | Change(s) to the test method(s) and/or specifications for the finished product                                                                                                                                                                                                                                                                                                                                                                                   | 28/07/2005                          | 10/08/2005                                  |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0016 | Change(s) to the test method(s) and/or specifications for the active substance                                                                                                                                                                                                                                                                                                                                                                                   | 28/07/2005                          | 10/08/2005                                  |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| R/0014  | Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 21/01/2004                          | 31/03/2004                                  | SPC, Annex II, Labelling, PL     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary    |
|---------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------|
|         | Renewal of the marketing authorisation                                                           |                                     |                                             |                                  |            |
| II/0013 | Update of or change(s) to the pharmaceutical documentation                                       | 25/09/2003                          | 02/10/2003                                  |                                  | authorised |
| N/0012  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 04/07/2003                          | 23/07/2003                                  | PL                               |            |
| II/0011 | Change(s) to the test method(s) and/or specifications for the finished product                   | 25/04/2003                          | 02/05/2003                                  | longer                           |            |
| I/0008  | 15a_Change in in-process controls applied during the manufacture of the product                  | 16/08/2002                          | 10/09/2002 no                               |                                  |            |
| I/0010  | 08_Change in the qualitative composition of immediate packaging material                         | 16/08/2002                          | 10/09/2002                                  |                                  |            |
| I/0009  | 17_Change in specification of the medicinal product                                              | 16/08/2002 product                  | 10/09/2002                                  |                                  |            |
| II/0007 | Update of Summary of Product Characteristics                                                     | 25/04/2002                          | 22/08/2002                                  | SPC                              |            |
| I/0006  | 20a_Extension of shelf-life or retest period of the active substance Medicinal                   | 15/02/2002                          | 15/02/2002                                  |                                  |            |
| II/0005 | Change(s) to the test method(s) and/or specifications for the finished product,                  | 27/06/2001                          | 04/07/2001                                  |                                  |            |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary    |
|---------|-----------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------|
|         | Change(s) to the manufacturing process for the active substance |                                     |                                             |                                  | authorised |
| II/0004 | Update of or change(s) to the pharmaceutical documentation      | 25/01/2001                          | 13/03/2001                                  |                                  |            |

## Opinion/ Notification 1 issued on Commission Decision Issued 2 / amended on Product Information affected 3 25/01/2001 13/03/2001 Medicinal product no longer authorised